Antheia and TAPI have formed a strategic partnership to accelerate global commercialization of Antheia’s biosynthetic manufacturing platform for key starting materials (KSMs) and active pharmaceutical ingredients (APIs). The collaboration integrates Antheia’s synthetic biology and fermentation-based production technology with TAPI’s large-scale bioprocessing, enzymatic, and manufacturing infrastructure across Europe.